Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
Kenneth G. Saag(University of Alabama at Birmingham), Margaret R. Warner(Eli Lilly (United States)), Richard Eastell(University of Sheffield), José Zanchetta(Universidad del Salvador), Jean‐Pierre Devogelaer(UCLouvain), Kelly Krohn(Eli Lilly (United States)), John H. Krege(Eli Lilly (United States)), Robert A. Adler(Hunter Holmes McGuire VA Medical Center), Kyoungah See(Eli Lilly (United States))
Cited by 494
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis Care & Research|2015|1.1k